Literature DB >> 1484095

High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample.

L Lennard1, H J Singleton.   

Abstract

A reversed-phase high-performance liquid chromatographic assay was developed to quantify intracellular metabolites of the cytotoxic drug 6-mercaptopurine in the human red blood cell. The 6-thioguanine nucleotides, 6-thioinosinic acid and 6-methylmercaptopurine metabolites are measured in a single sample. A similar assay measures the parent thiopurine compounds. The limit of quantitation of the assay is 0.03, 0.03 and 0.12 nmol per 8 x 10(8) red blood cells for the 6-thioguanine nucleotides, 6-thioinosinic acid and the 6-methylmercaptopurine metabolites, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1484095     DOI: 10.1016/0378-4347(92)80347-s

Source DB:  PubMed          Journal:  J Chromatogr


  39 in total

1.  Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?

Authors:  Luc J J Derijks; Daniel W Hommes
Journal:  Curr Gastroenterol Rep       Date:  2006-04

2.  The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine.

Authors:  M M T J Broekman; D R Wong; G J A Wanten; H M Roelofs; C J van Marrewijk; O H Klungel; A L M Verbeek; P M Hooymans; H-J Guchelaar; H Scheffer; L J J Derijks; M J H Coenen; D J de Jong
Journal:  Pharmacogenomics J       Date:  2017-01-03       Impact factor: 3.550

Review 3.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

4.  Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases.

Authors:  Aurélie Chapdelaine; Anne-Marie Mansour; Yves Troyanov; David R Williamson; Maxime Doré
Journal:  Clin Rheumatol       Date:  2017-01-27       Impact factor: 2.980

Review 5.  Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics.

Authors:  A Anstey
Journal:  J R Soc Med       Date:  1995-03       Impact factor: 5.344

6.  Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?

Authors:  H A Davies; L Lennard; J S Lilleyman
Journal:  BMJ       Date:  1993-05-08

7.  Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).

Authors:  Tadakazu Hisamatsu; Shingo Kato; Reiko Kunisaki; Minoru Matsuura; Masakazu Nagahori; Satoshi Motoya; Motohiro Esaki; Norimasa Fukata; Satoko Inoue; Takeshi Sugaya; Hirotake Sakuraba; Fumihito Hirai; Kenji Watanabe; Takanori Kanai; Makoto Naganuma; Hiroshi Nakase; Yasuo Suzuki; Mamoru Watanabe; Toshifumi Hibi; Masanori Nojima; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2019-04-30       Impact factor: 7.527

8.  Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.

Authors:  S Wright; D S Sanders; A J Lobo; L Lennard
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia.

Authors:  B M de Oliveira; M B Viana; C L Zani; A J Romanha
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

10.  The accumulation of mercaptopurine metabolites in age fractionated red blood cells.

Authors:  A Rostami-Hodjegan; L Lennard; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.